La vendita allo scoperto per Versus Systems dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Versus Systems. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Versus Systems (NASDAQ:VS) Azioni, Report sulle vendite allo scoperto

Versus Systems

Versus Systems Inc offers a suite of proprietary business-to-business software tools that are meant to drive user engagement through gamification and rewards. These tools allow its partners to offer in-game prizes and rewards, including merchandise, coupons, digital goods, and sweepstakes entries - inside their websites, their venues, or their streaming media content. Its customers are mostly sports teams, venues, and advertising agencies, which typically use its products as part of their live events or as part of an advertising campaign with the goal of engaging fans, increasing consented first-party data, and increasing sales. The company operates in Canada and the USA.

Versus Systems Inc

Vision Sensing Acquisition Corp. - Class A Common Stock

Vision Sensing Acquisition Corp

Vision Sensing Acquisition Corp. - Warrants

Viasat Inc

VIASAT ORD

VITASPRING BIOMEDICAL CO by VitaSpring Biomedical Co. Ltd.

VitaSpring Biomedical Co Ltd

VSBLTY Groupe Technologies Corp

VSBLTY GROUPE TECHNOLOGIS by VSBLTY GROUPE TECHNOLOGIES CORP.

Viscofan SA

Victoria's Secret & Co

VictoryShares Dividend Accelerator ETF

VSE Corp

VSee Health Inc

GREEN ECONOMY DEVELOPMENT by Green Economy Development Limited

Green Economy Development Ltd

Vanguard ESG International Stock ETF

Vishay Intertechnology, Inc. Common Stock

Vishay Intertechnology Inc

Virtus Newfleet Short Duration High Yield Bond ETF

VISHAY INTERTECH ORD

Vision Inc

Applied Finance Valuation Large Cap ETF

Vasamed Inc

VS Media Holdings Limited - Class A Ordinary Shares

VS Media Holdings Ltd

Verify Smart Corp

VictoryShares US Multi-Factor Minimum Volatility ETF

Verso

VISTA OIL & GAS SAB DE CV by Vista Energy S.A.B. de C.V.

Vista Energy SAB de CV

THREE SIXTY SOLAR LTD by THREE SIXTY SOLAR LTD.

Three Sixty Solar Ltd

Vesper

Viaspace Inc

VSPIKES Volatility of Volatility Index

VICTORY SQUARE TECH ORD by Victory Square Technologies Inc

Victory Square Technologies Inc

Voiceserve Inc

Vanguard FTSE All-Wld ex-US SmCp Idx ETF

VIKASA SPAC Series I Acquisition Corp

VALID SOLUCOES S/ADR by Valid Solucoes S.A

Valid Solucoes eServicos de Seguranca em Meios de Pagamento e Identificacao

Visionstate Corp

Voice Assist Inc

VGRD FTSE ALL WRLD EX US SML CAP ETF

Vistra Corp

Vasta Platform Limited - Class A Ordinary Shares

Vasta Platform Ltd

VISION TECHNOLOGY CORP by Vision Technology Corp.

Vision Technology Corp

Vast Renewables Limited - Ordinary Shares

Vast Renewables Ltd

VNV Global AB

Verastem Inc

Vista Outdoor Inc

Vestis Corp

VISTRA ORD

VOSS VEKSEL OG LNDMNDSBNK by VOSS VEKSEL OG LANDMANDSBANK ASA

Visiox Holdings, Inc

VSY - United States Dollar

Vesync Co Ltd

VISCOUNT SYSTEMS INC by Viscount Systems, Inc.

Viscount Systems Inc

v.systems

Venus SXP

Vice President Kamala Harris Fox News interview with Brett Baier has sparked considerable speculation among <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41363075/26m-bet-on-trumps-election-victory-fuels-speculation-of-coordinated-activity-on-polymarket">prediction market traders</a>.
What Happened: Polymarket traders <a href="https://polymarket.com/event/what-will-kamala-harris-say-during-fox-interview?tid=1729099568608">bet</a> there&#8217;s a 14% chance Kamala Harris will mention Donald Trump more than ten times during the discussion. The likelihood of her addressing crypto or Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is only 9%, despite recent outreach to Black male voters on this topic. 
The top subjects expected to be mentioned include Abortion (65%), Project 2025 (70%), Israel (74%) and Medical Records (54%).
The Hill on Wednesday <a href="https://thehill.com/homenews/campaign/4935173-harris-fox-news-interview-risks-opportunities/">reported</a> two theories regarding the Vice President&#8217;s decision to appear on what is commonly seen as a venue not traditionally disposed towards Democratic candidates. 
One is that she&#8217;s trying to appeal to conservative voters who are skeptical of GOP nominee Donald Trump due to his behavior and rhetoric. The other is that Harris doesn't expect to win over many Fox viewers but aims to counter criticism that she avoids tough or adversarial interviews.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/digital-assets"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/news/24/10/41348386/trump-falls-3-points-behind-harris-in-new-poll-economic-worries-dominate-voter-concerns-report">Trump Falls 3 Points Behind Harris In New Poll, Economic Worries Dominate Voter Concerns: Report</a>
Harris agreeing to the Fox interview stands in contrast to <a href="https://www.benzinga.com/general/entertainment/24/10/41282077/trump-rejects-debate-offers-from-fox-cnn-as-harris-agrees-to-town-hall-there-will-be-no-rem">former President Donald Trump rejecting debate offers</a> from the network. The Democratic nominee is reportedly also <a href="https://www.benzinga.com/general/entertainment/24/10/41324364/kamala-harris-eyes-appearance-on-joe-rogan-experience-to-appeal-to-male-voters-as-president">considering an appearance on the popular podcast</a>, &#8220;The Joe Rogan Experience,&#8221; to secure more male voters. 
This move, along with her Fox News appearance, indicates a strategic approach by the Harris campaign to engage with demographics outside of her traditional support base.
What&#8217;s Next: The influence of prediction markets on cryptocurrency adoption expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41365026/venture-capitalist-labels-gary-gensler-worst-crypto-regulator-ever-says-election-race-is-a">Venture Capitalist Labels Gary Gensler &#8216;Worst Crypto Regulator Ever,&#8217; Says Election Race Is A &#8216;Win-Win&#8217; For Crypto Investors</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$BTC

Kamala Harris's Fox News Interview Will Likely Mention Project 2025, Israel And One Other Contentious Topic, Polymarket Traders Speculate

WIIM

OCUL

Ocular Therapeutix shares are trading higher after Scotiabank Initiated coverage on the stock with a Sector Outperform rating and announced a $22 price target.

William Blair has initiated coverage on Apellis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) and notes that Apellis was the first company to successfully target complement C3, which has led to the approval of two therapies: Empaveli (systemic pegcetacoplan) for paroxysmal nocturnal hemoglobinuria and Syfovre (intravitreal pegcetacoplan) for geographic atrophy secondary to age-related macular degeneration.
William Blair writes that although Empaveli has established a solid position in the PNH market, short-term challenges are anticipated due to the emergence of a new competitor, Novartis AG&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Fabhalta (iptacopan).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40261396/apellis-pharmaceuticals-pegcetacoplan-meets-primary-goal-in-late-stage-study-in-patients-with-rar" rel="noreferrer noopener">Apellis Pharmaceuticals&#8217; Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases</a>.
However, Empaveli has a more significant market opportunity in C3 glomerulopathy (C3G) and immune-complex membranoproliferative glomerulonephritis (IC-MPGN), especially following the strong top-line results from the Phase 3 VALIANT study.
William Blair projects that it could receive approval by late 2025, with peak sales estimates for C3G and IC-MPGN reaching $700 million by 2031.
The analyst has initiated the coverage with an Outperform rating and estimates a fair value for <a target="_blank" href="https://www.benzinga.com/quote/APLS/analyst-ratings" rel="noreferrer noopener">shares of $50</a>.
Syfovre received approval in February 2023, while Astellas Pharma Inc&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ALPMF#OTC">ALPMF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ALPMY#OTC">ALPMY</a>) drug was approved in August 2023. According to the analyst, Syfovre presents a more attractive efficacy profile and a more advantageous label, permitting monthly or bi-monthly dosing and treatment beyond 12 months (although the label for Izervay may be updated to include these options in November). 
Nevertheless, the analyst notes that the market is sufficiently large to accommodate multiple blockbuster drugs.
Thus, even though Syfovre has a competitive advantage over Izervay, William Blair believes both medications can thrive in light of the extensive market, significant unmet needs, and the absence of alternative treatments.
With an assumption of only 30% peak market penetration among patients treated by injecting physicians and a consistent rise in referral rates without an increase in diagnosis rates, the analyst projects U.S. peak sales for Syfovre to reach $2.0 billion by 2030.
Price Action: APLS stock is down 0.95% at $27.68 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41364634/citigroup-remains-a-compelling-investment-opportunity-analysts-take-on-q3-performance" target="_blank" rel="noreferrer noopener">Citigroup Remains A Compelling Investment Opportunity: Analysts Take On Q3 Performance</a>.</li>
</ul>

Analyst Color

Biotech

Large Cap

Health Care

Price Target

Initiation

Analyst Ratings

Trading Ideas

General

ALPMF

ALPMY

APLS

Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch

NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares are trading higher Wednesday, rebounding from Tuesday&#8217;s sharp decline, as chip stocks across the board recover from heavy selling pressure. Here's a look at <a href="https://www.benzinga.com/news/earnings/24/10/41363734/asml-holding-stock-continues-to-slide-other-chipmakers-bounce-back-we-are-still-quite-optimistic-ab">what's driving the movement</a>.
What To Know: Nvidia shares fell more than 4% on Tuesday alongside several chipmakers amid multiple developments. 
Nvidia is at the center of U.S. policy discussions regarding AI chip exports, which may help explain some of the recent volatility. Bloomberg <a href="https://www.benzinga.com/markets/equities/24/10/41328454/why-nvidia-amd-and-other-chipmakers-are-moving-lower-in-tuesdays-premarket">reported</a> Tuesday that the Biden administration was weighing new export restrictions aimed at curbing the sale of advanced AI chips to countries seen as potential national security threats. 
While China is already subject to these restrictions, there is talk of expanding the controls to other nations, including those in the Persian Gulf, where AI infrastructure development has been accelerating.
The selloff in the broader chip sector on Tuesday was also partly driven by weak guidance from ASML Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>). The company <a href="https://www.benzinga.com/markets/equities/24/10/41339229/asml-earnings-leak-sparks-broad-semiconductor-sell-off-sector-down-sharply-as-dutch-chipmaker-lo">lowered its full-year sales forecast</a> due to weaker demand for non-AI chips. ASML shares plummeted 16%, dragging other chipmakers down with it.
Nvidia and other semiconductor stocks are bouncing back Wednesday. The rebound appears partly due to optimism around AI-related demand, with ASML CEO Christopher Fouquet stating that the company remains &#8220;quite optimistic&#8221; about the long-term growth in the AI segment on a conference call. Fouquet also noted that lower chip demand is mainly coming from the automobile and consumer electronics industries. 
"We are still quite optimistic about AI," Fouquet said Wednesday morning.
Check This Out: <a href="https://www.benzinga.com/government/24/10/41365885/lenovos-ai-push-grows-with-meta-nvidia-collaboration-outside-china">Lenovo&#8217;s AI Push Grows with Meta, Nvidia Collaboration Outside China</a>
NVDA Price Action: Nvidia shares were up 3.56% at $136.30 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="524" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16141812/NVDA-1024x524.png" alt="" class="wp-image-599017" style="width:551px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16141812/NVDA-1024x524.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16141812/NVDA-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16141812/NVDA-768x393.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16141812/NVDA.png 1456w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41365437/why-wisa-technologies-stock-is-gaining-wednesday">Why WiSA Technologies Stock Is Gaining Wednesday</a></li>
</ul>
Image via Shutterstock.

Movers

ASML

NVDA

Nvidia Shares Are Rising Wednesday: What's Going On?

The S&amp;P 500&nbsp;defies the odds and mounting risks to continue its trend. The market broke above critical support in late September and is on track to reach bull case targets near 6,000 by the year&#39;s end. The move was sparked by the Fed, which leans toward lower interest rates but is driven by the robust outlook for earnings. With the two forces seemingly in tandem, the 6,000 level may only be a stopping point on the way to even higher highs.&nbsp;
The S&amp;P 500&#39;s 6,000 target is derived technically and is likely low. Given the earnings and dividend growth outlook and assuming no change in the price multiple, the 15% growth expected for 2025 suggests a move to 6,600 is possible by the end of next year.&nbsp;
<h2>The S&amp;P 500 Uptrend Is Supported by Earnings Growth&nbsp;</h2>
The outlook for S&amp;P 500 earnings growth is driving the market today. Although the forecasts for FQ3 2024, FQ4, and the first half of next year have moderated since the summer, they remain strong at 4.1%, 14.2%, and 13.5%, respectively. The critical detail is that the FQ3 growth target, down sequentially from low double-digits, is a launch pad for sequential acceleration in Q4 and sustained double-digit growth in the first half of next year. Because the Fed is lowering rates and economic data remains healthy, the estimates for next year are likely too low.&nbsp;
The growth outlook for dividends and share repurchases also supports the uptrend in the S&amp;P 500. Not all S&amp;P 500 companies pay dividends or buy back shares, but most do, and some do both. The outlook is for sustained growth in 2025 at or above the pace set in 2024, mid-single-digits for the distribution and high-single-digits for repurchases. Goldman Sachs estimates predict that 2025 share repurchases will top $1 trillion, setting a record backed by earnings growth, lower interest rates, and resilient economic conditions.&nbsp;
The economic data has shown spotty weaknesses in 2024 but healthy overall, aligning with Goldman&#39;s forecast, with stronger-than-expected job growth and sustained wage inflation near 4.0%. A slowdown in GDP growth could provide a headwind for earnings growth, but the forecasted 2% to 2.5% is still solid and likely a low estimate.&nbsp;
<h2>Large Cap Tech Is Still the Focus: That May Change in 2025</h2>
Large-cap tech stock prices will likely increase in 2024 and early 2025. Still, volatility should be expected because the VIX remains elevated, and there are signs of technical weakness. The warning to investors is not to chase stock prices higher but to wait for price pullbacks before buying, stick with quality, and be ready to exit quickly.&nbsp;
Although the rally is expected to broaden to all sectors in 2025, including strength in healthcare, materials, communications, and technology, the focus will remain on large caps and AI. The communications and technology sectors will be the second and fourth fastest-growing, which means money will continue to flow into the leading names, including NVIDIA, Microsoft, Amazon (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amzn#NASDAQ">AMZN</a>), Google (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/goog#NASDAQ">GOOG</a>), and other AI-powered giants.&nbsp;
Among the risks for investors is concentration. The S&amp;P 500 is a market-cap-weighted index, so the more money flows into tech, the more impact it will have on the market when the AI bubble bursts. The top five holdings in the S&amp;P, including Apple, NVIDIA, Microsoft, and others mentioned, already account for 30% of the entire index, so the risk is real. Fed policy will eventually show up in the data and results, pointing to improving economic conditions and small-cap strength that could end the bull market for large-cap stocks.&nbsp;
<img alt="S&amp;P 500 SPX stock chart" class="aligncenter" src="https://www.marketbeat.com/logos/articles/med_20241014130443_chart-spy-10142024-002.png" style="height:446px; width:917px" />
The article &quot;<a href="https://www.marketbeat.com/originals/the-s-and-p-500-defies-odds-extends-rally-with-6-000-in-sight/">The S&amp;P 500 Defies Odds, Extends Rally With 6,000 in Sight</a>&quot; first appeared on MarketBeat.

Earnings

Dividends

Technicals

Economics

Federal Reserve

Markets

Tech

AMZN

GOOG

The S&P 500 Defies Odds, Extends Rally With 6,000 in Sight

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 300 points on Wednesday.
The Dow traded up 0.78% to 43,072.45 while the NASDAQ rose 0.32% to 18,374.03. The S&amp;P 500 also rose, gaining, 0.47% to 5,842.65.
Check This Out: <a href="https://www.benzinga.com/markets/24/10/41342689/top-3-tech-and-telecom-stocks-that-could-lead-to-your-biggest-gains-this-quarter">Top 3 Tech And Telecom Stocks That Could Lead To Your Biggest Gains This Quarter</a>
Leading and Lagging Sectors Utilities shares jumped by 1.6% on Tuesday.
In trading on Tuesday, communication services shares fell by 0.6%.
Top Headline
Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) reported better-than-expected third-quarter results.
The company posted adjusted EPS of $1.88, up from $1.38 a year ago, beating the consensus of $1.58, demonstrating the strength of Integrated Firm with strong results across business segments. Net earnings increased almost 33% to $3.2 billion. The U.S. bank reported third-quarter sales of $15.38 billion, up 15.9% year over year, beating the consensus of $14.41 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>180 Life Sciences Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) shares shot up 515% to $9.35. 180 Life Sciences interim CEO said that the company is planning to enter the online gaming industry with its newly acquired gaming technology platform.</li>
<li>Shares of Altus Power, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPS#NYSE">AMPS</a>) got a boost, surging 23% to $3.7050 after the company announced that a formal review of strategic alternatives has been underway by its Board of Directors. Also, the company reaffirmed its FY24 guidance.</li>
<li>Versus Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VS#NASDAQ">VS</a>) shares were also up, gaining 304% to $4.5699 after the company announced a $2.5 million investment and licensing agreement with ASPIS.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Service Properties Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SVC#NYSE">SVC</a>) shares dropped 17% to $3.9650 after the company announced actions to improve liquidity and reduce leverage. It reduced its quarterly dividend to 1 cent per share.</li>
<li>Shares of Silvaco Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVCO#NASDAQ">SVCO</a>) were down 29% to $7.90 after the company reported a decline in orders from Asia during third quarter and cut its FY24 revenue outlook.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) was down, falling 17% to $10.49 after the FDA placed a clinical hold on the company&#8217;s investigational new drug application for its COVID-19-influenza combination and standalone influenza vaccine candidates.</li>
</ul>
Commodities In commodity news, oil traded up 0.1% to $70.67 while gold traded up 0.5% at $2,691.70.
Silver traded up 0.7% to $31.985 on Wednesday, while copper rose 0.8% to $4.3730.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 fell 0.19%, Germany's DAX fell 0.27% and France's CAC 40 fell 0.40%. Spain's IBEX 35 Index rose 0.56%, while London's FTSE 100 gained 0.97%.
Asia Pacific Markets
Asian markets closed mostly lower on Wednesday, with Japan's Nikkei 225 falling 1.83%, Hong Kong's Hang Seng Index falling 0.16%, China's Shanghai Composite Index gaining 0.05% and India's BSE Sensex falling 0.39%.
Economics
<ul>
<li>U.S. mortgage applications fell by 17% from the previous week during the second week of October.</li>
<li>Export prices in the U.S. declined by 0.7% month-over-month in September, exceeding market estimates of a 0.4% fall.</li>
<li>Import prices declined by 0.4% from the previous month in September.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41329813/jim-cramer-we-need-more-uranium-recommends-this-stock-says-novo-nordisk-doesnt-hold-a-ca">&nbsp;</a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41329813/jim-cramer-we-need-more-uranium-recommends-this-stock-says-novo-nordisk-doesnt-hold-a-ca">Jim Cramer: &#8216;We Need More Uranium,&#8217; Recommends This Stock; Says Novo Nordisk &#8216;Doesn&#8217;t Hold A Candle&#8217; To Big Pharma Rival</a></li>
</ul>

Equities

Eurozone

Commodities

AMPS

ATNF

NVAX

SVCO

Nasdaq Moves Higher; Morgan Stanley Profit Beats Estimates

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/6228915026d7930001218ee4/matt-farrell">Piper Sandler analyst Matt Farrell</a> initiated coverage on The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) with a Neutral rating and announced a price target of $95. Disney shares closed at $94.22 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how </a><a href="https://www.benzinga.com/quote/dis/analyst-ratings">other </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">analysts view this stock</a>.</li>
<li>Stephens &amp; Co. analyst Charles Nabhan initiated coverage on Paycor HCM, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYCR#NASDAQ">PYCR</a>) with an Overweight rating and announced a price target of $18. Paycor HCM shares closed at $13.75 on Tuesday. <a href="https://www.benzinga.com/quote/PYCR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer analyst Michael Phillips initiated coverage on RLI Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLI#NYSE">RLI</a>) with a Perform rating. RLI shares closed at $160.24 on Tuesday. <a href="https://www.benzinga.com/quote/RLI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Michael Turrin initiated coverage on Autodesk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with an Overweight rating and announced a price target of $340. Autodesk shares closed at $286.48 on Tuesday. <a href="https://www.benzinga.com/quote/ADSK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Northland Capital Markets analyst Mike Grondahl initiated coverage on MoneyLion Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ML#NYSE">ML</a>) with an Outperform rating and announced a price target of $60. MoneyLion shares closed at $44.60 on Tuesday. <a href="https://www.benzinga.com/quote/ML/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ADSK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="493" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16145045/image-131-1024x493.png" alt="" class="wp-image-599101" style="width:646px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16145045/image-131-1024x493.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16145045/image-131-300x145.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16145045/image-131-768x370.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16145045/image-131.png 1355w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41358280/united-airlines-posts-upbeat-earnings-joins-morgan-stanley-u-s-bancorp-and-other-big-stocks-moving-h">United Airlines Posts Upbeat Earnings, Joins Morgan Stanley, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday</a></li>
</ul>

ADSK

PYCR

This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

UXIN

Uxin shares are trading higher after the company announced a strategic partnership with Wuhan City Economic & Technological Development Zone.

<a href="https://www.wsj.com/business/media/nbcuniversal-to-stream-local-sports-on-peacock-in-bid-for-cord-cutters-68e1d941?mod=latest_headlines" title="https://www.wsj.com/business/media/nbcuniversal-to-stream-local-sports-on-peacock-in-bid-for-cord-cutters-68e1d941?mod=latest_headlines">https://www.wsj.com/business/media/nbcuniversal-to-stream-local-sports-on-peacock-in-bid-for-cord-cutters-68e1d941?mod=latest_headlines</a>

CMCSA

NBCUniversal To Add Regional Sports Channels To Peacock Streaming Service Starting In Early 2025, Including Boston, Philadelphia, And Northern California Markets

Walgreens Boots Alliance Inc (NASDAQ: WBA) reported fourth-quarter fiscal year 2024 sales of $37.55 billion on Tuesday. 
That&#8217;s up 6% year over year (+6.1% on constant currency). The numbers beat the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $35.76 billion</a>, reflecting sales growth across all segments.
Walgreens Boots Alliance announced a footprint optimization program targeting approximately 1,200 closures over the next three years. This includes approximately 500 closures in fiscal 2025, which will be immediately accretive to adjusted <a href="https://www.benzinga.com/news/earnings/24/10/41333092/walgreens-boots-alliance-outlines-three-cost-saving-strategy-as-q4-earnings-beat-street-estimates" target="_blank" rel="noreferrer noopener">EPS and free cash flow</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41279374/cvs-health-positioned-for-medicare-margin-expansion-and-market-share-gains-says-bar" rel="noreferrer noopener">CVS Health Positioned For Medicare Margin Expansion And Market Share Gains, Says Barclays Analyst</a>.
The company said it exceeded fiscal 2024 targets for&nbsp;$1 billion&nbsp;in cost savings,&nbsp;a $600 million&nbsp;reduction in capital expenditures, and&nbsp;$500 million&nbsp;in working capital initiatives.
Truist Securities noted that Walgreens Boots Alliance finished the fiscal year 2024 on a strong note, meeting management&#8217;s expectations and exceeding projections for both revenue and earnings.
The fiscal 2025 guidance reflects optimism, aligning with the higher end of Truist Securities&#8217; and consensus forecasts.
Both international and U.S. healthcare segments delivered solid performances despite ongoing challenges in consumer spending and pharmacy reimbursement pressures. However, the outlook on reimbursement was positive. Fourth-quarter cash flow surpassed expectations and remains a critical focus, while capital expenditures and working capital improvements are encouraging.
Truist <a target="_blank" href="https://www.benzinga.com/quote/WBA/analyst-ratings" rel="noreferrer noopener">maintains the Hold rating</a>, with a price target of $10.
RBC Capital notes that Walgreens Boots Alliance has outlined its planned store closures through 2027, offering greater clarity and reducing the uncertainty around the higher end of potential closures.
The analyst also highlights that Walgreens is investing in locations it anticipates will absorb prescriptions and foot traffic from the closing stores. 
Having already shuttered a few hundred locations in fiscal year 2024, the company has recent experience managing patient transitions and prescription volumes.
Evercore ISI maintains Walgreens Boots Alliance with an In-Line rating and raises the price target from $7.5 to $10.
Price Action: WBA stock is up 4.32% at $10.87 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41362705/sofi-boosts-payment-services-with-galileos-cloud-based-cyberbank-core" target="_blank" rel="noreferrer noopener">SoFi Boosts Payment Services with Galileo&#8217;s Cloud-Based Cyberbank Core</a>.</li>
</ul>
Image: Shutterstock

Walgreens Boots Alliance Analysts Expect Strategic Plans Will Boost Investor Confidence In 2025

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the consumer staples sector.
<h3 class="wp-block-heading">Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>)</h3>
<ul>
<li>Dividend Yield: 9.16%</li>
<li>Morgan Stanley analyst Erin Wright maintained an Underweight rating and cut the price target from $9 to $7 on Oct. 11. This analyst has an accuracy rate of 75%.</li>
<li>Truist Securities analyst David Macdonald maintained a Hold rating and cut the price target from $13 to $10 on Oct. 7. This analyst has an accuracy rate of 74%</li>
<li>Recent News: On Tuesday, Walgreens reported fourth-quarter fiscal year 2024 sales of $37.55 billion, up 6% year over year (+6.1% on constant currency), beating the consensus of $35.76 billion, reflecting sales growth across all segments.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101624&amp;t=be2bearmibe3na1">latest WBA news</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="913" height="841" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143111/image-127.png" alt="" class="wp-image-599050" style="width:538px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143111/image-127.png 913w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143111/image-127-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143111/image-127-768x707.png 768w" sizes="(max-width: 913px) 100vw, 913px" /></a></figure>
<h3 class="wp-block-heading">Conagra Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>)</h3>
<ul>
<li>Dividend Yield: 4.73%</li>
<li>B of A Securities analyst Bryan Spillane maintained a Neutral rating and cut the price target from $34 to $33 on Oct. 3. This analyst has an accuracy rate of 65%.</li>
<li>Evercore ISI Group analyst David Palmer maintained a Neutral rating and lowered the price target from $32 to $31 on July 12. This analyst has an accuracy rate of 68%.</li>
<li>Recent News: On Oct. 2, ConAgra Brands reported worse-than-expected first-quarter financial results.</li>
<li>Benzinga Pro's real-time newsfeed alerted t<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101624&amp;t=be2bearmibe3na1">o latest CAG news.</a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="903" height="835" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143147/image-128.png" alt="" class="wp-image-599053" style="width:648px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143147/image-128.png 903w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143147/image-128-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143147/image-128-768x710.png 768w" sizes="(max-width: 903px) 100vw, 903px" /></a></figure>
<h3 class="wp-block-heading">Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>)</h3>
<ul>
<li>Dividend Yield: 4.47%</li>
<li>Goldman Sachs analyst Bonnie Herzog maintained a Buy rating and raised the price target from $126 to $140 on Sept. 26. This analyst has an accuracy rate of 69%.</li>
<li>Barclays analyst Gaurav Jain maintained an Overweight rating and boosted the price target from $130 to $145 on Sept. 9. This analyst has an accuracy rate of 68%.</li>
<li>Recent News: Philip Morris will host a live audio webcast on Tuesday, Oct. 22 to discuss its third-quarter results.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101624&amp;t=be2bearmibe3na1">trend in PM stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="846" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143219/image-129.png" alt="" class="wp-image-599056" style="width:696px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143219/image-129.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143219/image-129-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143219/image-129-768x716.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:<a href="https://www.benzinga.com/news/24/10/41358280/united-airlines-posts-upbeat-earnings-joins-morgan-stanley-u-s-bancorp-and-other-big-stocks-moving-h"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41358280/united-airlines-posts-upbeat-earnings-joins-morgan-stanley-u-s-bancorp-and-other-big-stocks-moving-h">United Airlines Posts Upbeat Earnings, Joins Morgan Stanley, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday</a></li>
</ul>

Wall Street's Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields

Zimmer Biomet Holdings, Inc.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/zbh#NYSE">ZBH</a>) is scheduled to report third-quarter 2024 results on Oct. 30, before market open.
In the last reported quarter, the company&#39;s earnings of $2.01 beat the Zacks Consensus Estimate by 1.5%. ZBH beat on earnings in each of the trailing four quarters, the average surprise being 2.84%.
<h2>ZBH&#39;s Q3 Estimates</h2>
The Zacks Consensus Estimate for revenues is pegged at $1.81 billion, suggesting a 3.3% rise from the year-ago reported figure.
The Zacks Consensus Estimate for earnings is pinned at $1.75 per share, indicating a 6.1% improvement from the year-ago reported numbers.
<h2>Estimate Revision Trend Ahead of ZBH&#39;s Q3 Earnings</h2>
The Zacks Consensus Estimate for earnings has moved south 1.1%&nbsp; to $1.75 per share in the past 30 days.
Let&#39;s briefly look at how things might have shaped up for this MedTech major in the to-be-reported quarter.
<h2>Factors at Play</h2>
Zimmer Biomet is likely to have experienced strong growth in the&nbsp;third quarter on the back of strong performance from its business segments.
The Hip business is expected to have witnessed growth due to the company&#39;s comprehensive suite of solutions in navigation in direct anterior stems and surgical impactors.
While this business lagged&nbsp;the broader market during the second quarter due to key portfolio gaps, the company has made significant progress with new product introductions. During the same quarter, Zimmer Biomet launched the&nbsp;surgical impactor HAMMR, whose adoption has been great so far. Additionally, during the&nbsp;third-quarter, the company entered into a definitive agreement to acquire OrthoGrid Systems, Inc. The acquisition includes OrthoGrid&#39;s AI-powered, fluoroscopy-based surgical assistance platform&nbsp;Hip AI, as well as two additional FDA-cleared orthopedic applications and over 40 patents.
Outside the United States, ZBH expects to launch a second generation of hip posterior robotics. Banking on these developments, the company is expected to report a strong revenue increase within this category in the third quarter.
Within the Knees business, the company faced some challenges from a supply standpoint. These are high ASP cases.
<h2>Zimmer Biomet Holdings, Inc. Price and EPS Surprise</h2>
<div class="chart_embed"><img alt="Zimmer Biomet Holdings, Inc. Price and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/50/1729087518.png" style="height:263px; width:544px" title="" />
Zimmer Biomet Holdings, Inc. price-eps-surprise | Zimmer Biomet Holdings, Inc. Quote
</div>
Although this business in the United States was softer than expected, the company delivered knee growth of 5% year over year in the second quarter. We expect this growth trend to have continued in the third quarter as well.&nbsp;
The company expects to launch two different ROSA for knees in the coming three to eight quarters. In addition to ROSA, Zimmer Biomet has a partnership with THINK Surgical for TMINI &mdash; a&nbsp;miniature handheld robotic system for total knee arthroplasty. TMINI was supposed to be released in the second half of 2024. These developments might have had a positive impact on the company&#39;s third-quarter top-line performance.
In the second quarter, the S.E.T business grew mid-single digits, led by key focus areas of CMFT, upper extremities and sports growing on average high-single digits. The second quarter of 2024 was the third quarter in a row to experience such growth. Every single business within S.E.T. grew for the first time in the&nbsp;second quarter. We expect this trend to have continued in the third quarter as well.
<h2>What Our Model Suggests for ZBH</h2>
Per our proven model, a stock with a positive&nbsp;Earnings ESP&nbsp;and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a higher chance of beating estimates. This is not the case here, as you can see below.
Earnings ESP: Zimmer Biomet has an Earnings ESP of -1.65%%.
Zacks Rank: The company currently carries a Zacks Rank #4 (Strong).
<h2>Stocks Worth a Look</h2>
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle.
Atea Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avir#NASDAQ">AVIR</a>) has an Earnings ESP of +13.13% and a Zacks Rank #1 at present.
The company is expected to release third-quarter 2024 results on Nov. 13. AVIR&#39;s earnings surpassed estimates in two of the trailing four quarters and missed in the other two, the average surprise being 5.23%.
RadNet&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdnt#NASDAQ">RDNT</a>)&nbsp;has an Earnings ESP of +20.00% and a Zacks Rank #2 at present. The company is expected to release third-quarter 2024 results on Nov. 13.
RDNT&#39;s earnings surpassed estimates in three of the trailing four quarters and broke even once, the average surprise being 98.23%. The Zacks Consensus Estimate for RadNet&#39;s third-quarter EPS is expected to increase 21.4% from the year-ago quarter&#39;s reported numbers.
TransMedics Group&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) has an Earnings ESP of +26.63% and a Zacks Rank #3 at present. The company is likely to release third-quarter 2024 results on Nov. 4. The Zacks Consensus Estimate for the company&#39;s third-quarter EPS implies a surge of 333.3% from the year-ago quarter&#39;s reported figure.
<a href="https://www.zacks.com/stock/news/2351618/zbh-gears-up-for-q3-earnings-what-lies-ahead-for-the-stock?cid=CS-BENZ-FT-analyst_blog|earnings_preview-2351618">To read this article on Zacks.com click here.</a>

Earnings Beats

Mid Cap

Penny Stocks

Small Cap

AVIR

RDNT

TMDX

ZBH Gears Up for Q3 Earnings: What Lies Ahead for the Stock?

It's no secret that cannabis companies are facing some formidable challenges when it comes to raising capital, thanks to marijuana&#8217;s onerous classification as a <a href="https://www.benzinga.com/markets/cannabis/24/02/36916329/is-marijuana-a-controlled-substance-wait-what-is-a-controlled-substance" target="_blank" rel="noreferrer noopener">Schedule I controlled substance</a> under federal law. But now with potential changes on the horizon, such as cannabis rescheduling and banking reform, more companies just might improve their financial positions and attract new investments.
Even now, in anticipation of potential regulatory changes, there's been an increase in capital raises. Frank Colombo, managing director of data analytics and investment banking at Viridian Capital Advisors, provided an overview of capital raising trends the <a href="https://www.benzinga.com/markets/cannabis/24/10/41297836/exclusive-tracking-every-cannabis-deal-is-a-lot-of-fun-says-financial-expert-behind-essential-in">Benzinga Cannabis Capital Conference</a>. He told the crowd gathered in Chicago there&#8217;s been an increase of 14.8% in capital raises in 2024, driven mostly by Canadian equities and U.S. debt.
Colombo said U.S. debt accounts for over 50% of capital raises, indicating a reliance on debt financing rather than equity in the market. Retail and cultivation sectors are responsible for half of all capital raises. However, out of 12 different sectors, &#8220;investments in M&amp;A" were &#8220;really up,&#8221; <a href="https://www.benzinga.com/markets/cannabis/24/10/41297836/exclusive-tracking-every-cannabis-deal-is-a-lot-of-fun-says-financial-expert-behind-essential-in">he explained.</a>
<h3 class="wp-block-heading">But Still&#8230;Cannabis Debt Looms</h3>
Green Market Report's Debra Borchardt took a closer look at what she called it "a tsunami of debt headed straight for the cannabis industry," or approximately $1.83 billion of the debt that's due by 2026 that many public marijuana operators opted for earlier as they lacked much-needed capital.
According to regulatory filings for the publicly traded businesses in the industry large cannabis operators Curaleaf Holdings, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>), Cresco Labs (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>), Trulieve Cannabis Corp. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/TRUL#CSE">TRUL</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTCQX">TCNNF</a>) and Verano Holdings (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/VRNOF#OTCQX">VRNOF</a>) are about to face debt maturities in 2026, <a href="https://www.greenmarketreport.com/tsunami-of-debt-heading-toward-the-biggest-cannabis-companies/">explained</a> Borchardt who was also a guest at Benzinga&#8217;s conference in Chicago.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41258536/exclusive-cannabis-companies-must-get-more-juice-from-the-same-squeeze-says-cresco-labs-ceo-as-c">EXCLUSIVE: Cannabis Companies Must &#8216;Get More Juice From The Same Squeeze,&#8217; Says Cresco Labs CEO As Challenges Persist</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
While these companies have yet to navigate considerable debt challenges while focusing on their growth and operations, other big players in the space have successfully managed their respective debts, at least for now.
Borchardt highlighted Ascend Wellness Holdings' (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AAWH#OTC">AAWH</a>) and Green Thumb Industries Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/GTII#CSE">GTII</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTCQX">GTBIF</a>) "preemptive actions" to address their growing debt issues while mentioning TerrAscend Corp.&#8217;s (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TSND#TSX">TSND</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/TSNDF#OTCQX">TSNDF</a>) FG Loan which will mature in 2028.
New York-headquartered Ascend closed its <a href="https://www.benzinga.com/markets/cannabis/24/07/39776292/ascend-wellness-to-issue-235m-of-senior-secured-notes-to-prepay-215m-under-term-loan">previously announced</a> private placement of $235 million of 12.75% senior secured notes due 2029 in July with plans to prepay $215 million of principal amounts <a href="https://www.benzinga.com/markets/cannabis/24/07/39839510/ascend-wellness-cannabis-co-closes-235m-private-placement-of-senior-secured-notes-refinances-exi">outstanding under its existing term loan.</a>
Meanwhile, the owner of RISE Dispensaries closed on a $150 million 5-year syndicated credit facility led by Valley National Bank, the principal subsidiary of Valley National Bancorp which will allow it to retire its $225 million <a href="https://www.benzinga.com/markets/cannabis/24/09/40834346/cannabis-giant-green-thumb-secures-150m-credit-facility-strengthens-our-already-clean-balance-sh">senior secured debt due April 30, 2025.</a>
Jason Wild, executive chairman of TerrAscend said the <a href="https://www.benzinga.com/markets/cannabis/24/08/40133450/terrascend-cannabis-wraps-up-140m-debt-financing-no-other-material-debt-maturing-until-2027-says">recent completion</a> of the second and final draw of $26 million as part of its $140 million senior secured term loan, <a href="https://www.benzinga.com/markets/cannabis/24/10/41130165/cannabis-company-terrascend-secures-second-and-final-26m-loan-reduces-debt-in-michigan">enabled the company to have</a> "no other material debt maturing until late 2027."
<h3 class="wp-block-heading">Financial Institutions Set To Earn Billions In Interest Revenue</h3>
A new report from Whitney Economics backed by CTrust and Green Check projects that the U.S. cannabis industry will need between $65.6 billion and $130.7 billion in sustainable growth capital to support new cannabis businesses and help refinance existing ones over the next decade.
On the flip side, the market will generate roughly $1 billion to $2.4 billion in potential interest revenue for financial institutions willing to lend to cannabis businesses, over the same period, <a href="https://www.benzinga.com/markets/cannabis/24/10/41335229/cannabis-industrys-130b-growth-potential-top-states-for-investment-as-financial-institutions-set">according to the report.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41241003/exclusive-cannabis-rescheduling-is-not-cure-all-for-industry-problems-experts-explain-how-tax-ta">Cannabis Industry&#8217;s $130B Growth Potential: Top States For Investment As Financial Institutions Set To Earn Billions In Interest Revenue, New Report Reveals</a></li>
</ul>

Cannabis

Financing

AAWH

CRLBF

CSE:GTII

CSE:TRUL

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

GTBIF

GTII

TCNNF

TRUL

TSNDF

TSX:TSND

VRNOF

Cannabis Debt Looms For These Weed Giants: Here's How Some Tackled Their Financial Challenges

Investors with a lot of money to spend have taken a bearish stance on Stride (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LRN#NYSE">LRN</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with LRN, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 9 options trades for Stride.
This isn't normal.
The overall sentiment of these big-money traders is split between 33% bullish and 44%, bearish.
Out of all of the options we uncovered, 8 are puts, for a total amount of $322,830, and there was 1 call, for a total amount of $101,600.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $55.0 and $80.0 for Stride, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Stride options trades today is 652.86 with a total volume of 2,003.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Stride's big money trades within a strike price range of $55.0 to $80.0 over the last 30 days.
<h3>Stride Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729104351_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LRN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$4.0</td>
<td>$3.9</td>
<td>$4.0</td>
<td>$70.00</td>
<td>$101.6K</td>
<td style="text-align: right;">77</td>
<td style="text-align: right;">273</td>
</tr>
<tr>
<td>LRN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$5.4</td>
<td>$2.75</td>
<td>$4.0</td>
<td>$55.00</td>
<td>$80.0K</td>
<td style="text-align: right;">71</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>LRN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$12.4</td>
<td>$11.4</td>
<td>$11.76</td>
<td>$80.00</td>
<td>$47.0K</td>
<td style="text-align: right;">491</td>
<td style="text-align: right;">40</td>
</tr>
<tr>
<td>LRN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$5.2</td>
<td>$5.0</td>
<td>$5.1</td>
<td>$65.00</td>
<td>$42.8K</td>
<td style="text-align: right;">712</td>
<td style="text-align: right;">25</td>
</tr>
<tr>
<td>LRN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$6.4</td>
<td>$3.7</td>
<td>$4.5</td>
<td>$75.00</td>
<td>$33.3K</td>
<td style="text-align: right;">542</td>
<td style="text-align: right;">84</td>
</tr>
</tbody>
</table>

<h3>About Stride</h3>
Stride Inc is an American online educational company. It offers alternative programs to traditional on-campus schooling. It also operates state-funded virtual charter schools around the United States. The educational programs for K-12 students are usually monitored by parents and provide virtual classroom environments where teachers meet with students online, by phone, or in-person. The company's contractual agreements with various school districts to offer its curriculum programs provide a majority of the company's revenue. The company lines of business are Managed Public School Programs, Institutional, and Private Pay Schools and Other.
Following our analysis of the options activities associated with Stride, we pivot to a closer look at the company's own performance.
<h3>Stride's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 2,840,323, the LRN's price is down by -2.68%, now at $68.7. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 6 days.</li>
</ul>
<h3>What Analysts Are Saying About Stride</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $90.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Barrington Research keeps a Outperform rating on Stride with a target price of $90. 
&#x2A; Maintaining their stance, an analyst from Barrington Research continues to hold a Outperform rating for Stride, targeting a price of $90. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Stride with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Spotlight on Stride: Analyzing the Surge in Options Activity

Deep-pocketed investors have adopted a bullish approach towards Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NET usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Cloudflare. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 50% bearish. Among these notable options, 2 are puts, totaling $78,475, and 8 are calls, amounting to $451,000.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $70.0 to $110.0 for Cloudflare over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Cloudflare stands at 570.12, with a total volume reaching 1,625.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Cloudflare, situated within the strike price corridor from $70.0 to $110.0, throughout the last 30 days.
<h3>Cloudflare 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729104346_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NET</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$23.65</td>
<td>$22.95</td>
<td>$23.23</td>
<td>$70.00</td>
<td>$76.6K</td>
<td>27</td>
<td style="text-align: right;">33</td>
</tr>
<tr>
<td>NET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$21.95</td>
<td>$21.2</td>
<td>$21.68</td>
<td>$70.00</td>
<td>$71.5K</td>
<td>60</td>
<td style="text-align: right;">33</td>
</tr>
<tr>
<td>NET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.68</td>
<td>$2.62</td>
<td>$2.68</td>
<td>$110.00</td>
<td>$67.2K</td>
<td>1.6K</td>
<td style="text-align: right;">255</td>
</tr>
<tr>
<td>NET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$3.15</td>
<td>$2.64</td>
<td>$3.15</td>
<td>$90.00</td>
<td>$62.0K</td>
<td>1.2K</td>
<td style="text-align: right;">543</td>
</tr>
<tr>
<td>NET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$4.65</td>
<td>$4.6</td>
<td>$4.6</td>
<td>$94.00</td>
<td>$51.0K</td>
<td>206</td>
<td style="text-align: right;">119</td>
</tr>
</tbody>
</table>

<h3>About Cloudflare</h3>
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
In light of the recent options history for Cloudflare, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Cloudflare's Current Market Status</h3>
<ul>
<li>With a trading volume of 1,376,225, the price of NET is down by -2.39%, reaching $91.56.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 22 days from now.</li>
</ul>
<h3>What The Experts Say On Cloudflare</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $65.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Exane BNP Paribas lowers its rating to Underperform with a new price target of $65.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Cloudflare with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Unpacking the Latest Options Trading Trends in Cloudflare

High-rolling investors have positioned themselves bullish on Elastic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in ESTC often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 9 options trades for Elastic. This is not a typical pattern.
The sentiment among these major traders is split, with 33% bullish and 33% bearish. Among all the options we identified, there was one put, amounting to $72,250, and 8 calls, totaling $493,658.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $80.0 to $85.0 for Elastic over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Elastic's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Elastic's whale trades within a strike price range from $80.0 to $85.0 in the last 30 days. 
<h3>Elastic Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729104341_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESTC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$9.8</td>
<td>$9.5</td>
<td>$9.7</td>
<td>$80.00</td>
<td>$184.2K</td>
<td>1.2K</td>
<td style="text-align: right;">330</td>
</tr>
<tr>
<td>ESTC</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$9.7</td>
<td>$9.5</td>
<td>$9.6</td>
<td>$80.00</td>
<td>$98.8K</td>
<td>1.2K</td>
<td style="text-align: right;">104</td>
</tr>
<tr>
<td>ESTC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$8.5</td>
<td>$8.4</td>
<td>$8.5</td>
<td>$85.00</td>
<td>$72.2K</td>
<td>124</td>
<td style="text-align: right;">85</td>
</tr>
<tr>
<td>ESTC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$10.2</td>
<td>$9.9</td>
<td>$10.1</td>
<td>$80.00</td>
<td>$64.6K</td>
<td>1.2K</td>
<td style="text-align: right;">521</td>
</tr>
<tr>
<td>ESTC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$9.8</td>
<td>$9.7</td>
<td>$9.7</td>
<td>$80.00</td>
<td>$33.9K</td>
<td>1.2K</td>
<td style="text-align: right;">365</td>
</tr>
</tbody>
</table>

<h3>About Elastic</h3>
Elastic is a software company based in Mountain View, California, focusing on search-adjacent products. Its search engine allows it to process both structured and unstructured data while gleaning insights from that data. The firm's primary focus is on enterprise search, observability, and security.
After a thorough review of the options trading surrounding Elastic, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Elastic Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 314,355, the ESTC's price is up by 0.66%, now at $82.72. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 44 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Elastic with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

ESTC

Market Whales and Their Recent Bets on ESTC Options

MoneyLion shares are trading higher after Northland Capital Markets initiated coverage on the stock with an Outperform rating and announced a $60 price target.

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) with a Buy and maintains $30 price target.

Reiteration

ASPN

HC Wainwright & Co. Reiterates Buy on Aspen Aerogels, Maintains $30 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587639df5064ed0001400135/david-manthey">Baird analyst David Manthey</a> upgraded the rating for W.W. Grainger, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>) from Neutral to Outperform and raised the price target from $975 to $1,230. Grainger shares closed at $1,085.57 on Tuesday. <a href="https://www.benzinga.com/quote/GWW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst David Begleiter upgraded Westlake Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) from Underperform to Neutral and boosted the price target from $151 to $159. Westlake shares closed at $141.80 on Tuesday. <a href="https://www.benzinga.com/quote/WLK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Atif Malik upgraded the rating for Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) from Neutral to Buy and increased the price target from $52 to $62. Cisco shares closed at $54.08 on Tuesday. <a href="https://www.benzinga.com/quote/CSCO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cleveland Research upgraded the rating for SAP SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) from Neutral to Buy. SAP shares closed at $229.52 on Tuesday. <a href="https://www.benzinga.com/quote/SAP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Steven Seedhouse upgraded Wave Life Sciences Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) from Outperform to Strong Buy and increased the price target from $13 to $22. WAVE Life Sciences shares closed at $8.56 on Tuesday. <a href="https://www.benzinga.com/quote/WVE/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CSCO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="517" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130-1024x517.png" alt="" class="wp-image-599072" style="width:632px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130-1024x517.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130-768x388.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130.png 1297w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More:<a href="https://www.benzinga.com/news/24/10/41358280/united-airlines-posts-upbeat-earnings-joins-morgan-stanley-u-s-bancorp-and-other-big-stocks-moving-h"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41358280/united-airlines-posts-upbeat-earnings-joins-morgan-stanley-u-s-bancorp-and-other-big-stocks-moving-h">United Airlines Posts Upbeat Earnings, Joins Morgan Stanley, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday</a></li>
</ul>

Upgrades

CSCO

This Cisco Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Brookdale Senior Living shares are trading higher after Jefferies initiated coverage on the stock with a Buy rating and announced a $8 price target.

Roadzen Inc., Ocean Power Technologies, and Versus Systems are the 3 Penny Stocks to watch on July 4, based on&nbsp;TipRanks' Penny Stock Screener ...

3 Penny Stocks to Watch Now, 7/4/24

Executive reshuffles: NIO, Pfizer and Spirit Airlines in focus

Warning: VS is at high risk of performing badly

Versus Systems appoints new interim CFO

The latest update is out from Versus Systems (VS). Versus Systems Inc. has appointed Geoff Deller as their new Chief Financial Officer, with immedi...

Versus Systems Welcomes Geoff Deller as New CFO

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Versus Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/vs-stock-quote/">VS</a>) just reported results for the second quarter of 2024.<ul><li>Versus Systems reported earnings per share of -54 cents. This was below the analyst estimate for EPS of -50 cents.</li><li>The company reported revenue of $26,937.</li><li>This was 46.13% worse than the analyst estimate for revenue of $50,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/vs-stock-earnings-versus-systems-for-q2-of-2024/">VS Stock Earnings: Versus Systems Misses EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

VS Stock Earnings: Versus Systems Misses EPS, Misses Revenue for Q2 2024

Versus Systems (VS – Research Report), the Technology sector company, was revisited by a Wall Street analyst today. Analyst Scott Buck from H.C. Wa...

Hold Rating on Versus Systems Amid Financial Challenges and Uncertain Growth Prospects

Versus Systems receives Nasdaq notification regarding minimum stockholders' equity deficiency

Versus Systems (VS) has released an update. Versus Systems Inc. has been notified by NASDAQ of its insufficient stockholders' equity, falling below...

Comments

Versus Systems

Vendite allo scoperto

Versus Systems (NASDAQ:VS) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO